Is TELK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

248 people get TELK articles and Market Currents by email alert.

Get email alerts on TELK »

HEADLINES:

Telik Announces First Quarter 2013 Financial Results

PR Newswire (May 10, 2013)
Telik: A Possible Investment, But Only After Much Consideration
Chemistfrog • Fri, Apr 5 • 1 Comment
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance

PR Newswire (Mar 15, 2013)
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Is There Value In Telik?
InvestorR • Thu, Jan 24 • 8 Comments
Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome

PR Newswire (Jan 22, 2013)
The Long And Short Cases For Telik
InvestorR • Wed, Jan 16 • 1 Comment
Between A Rock And A Hard Place: Telik Needs Cash
PropThink • Mon, Jan 14
Is It Time To Go Long Or Short Telik?
EnhydrisPECorp • Sun, Jan 13 • 4 Comments
Telik Announces Orphan Designation Of Telintra® For Treatment Of Myelodysplastic Syndrome

PR Newswire (Jan 11, 2013)
Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology

PR Newswire (Dec 12, 2012)
Is Telik A Good Buy After Increasing 24% In One Day?
C.R. Jackson • Wed, Dec 12, 2012 • 1 Comment
What Is So Exciting About MEI Pharma?
C.R. Jackson • Fri, Nov 16, 2012 • 2 Comments
Telik Announces Third Quarter 2012 Financial Results

PR Newswire (Nov 9, 2012)
5 Stocks Trading Below Net Cash - Part VI
Markus Aarnio • Tue, Aug 28, 2012 • 2 Comments
Telik Announces Second Quarter 2012 Financial Results

PR Newswire (Aug 10, 2012)
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome

PR Newswire (May 15, 2012)
Telik Announces First Quarter 2012 Financial Results

PR Newswire (May 9, 2012)
Telik Regains Compliance With Minimum Bid Price Requirement

PR Newswire (Apr 17, 2012)
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference

PR Newswire (Jan 4, 2012)

To learn more about Seeking Alpha Pro, click here.

Telik: A Possible Investment, But Only After Much Consideration
Chemistfrog • Fri, Apr 5 • 1 Comment
Is There Value In Telik?
InvestorR • Thu, Jan 24 • 8 Comments
The Long And Short Cases For Telik
InvestorR • Wed, Jan 16 • 1 Comment
Between A Rock And A Hard Place: Telik Needs Cash
PropThink • Mon, Jan 14
Is It Time To Go Long Or Short Telik?
EnhydrisPECorp • Sun, Jan 13 • 4 Comments
Is Telik A Good Buy After Increasing 24% In One Day?
C.R. Jackson • Wed, Dec 12, 2012 • 1 Comment
Telik Jumps After FDA OKs Phase III Trial Resumption
SA Editor Eli Hoffmann • Mon, Oct 15, 2007
Icahn Raises Stake In Telik
Lon Juricic • Thu, Jan 18, 2007
Telik Plummets After Its Only Drug Fails Phase-3 Testing
SA Editors • Wed, Dec 27, 2006
Telik Blowup and the Case Against Efficient Market Theory
Roger Nusbaum • Tue, Dec 26, 2006

How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
What Is So Exciting About MEI Pharma?
C.R. Jackson • Fri, Nov 16, 2012 • 2 Comments
5 Stocks Trading Below Net Cash - Part VI
Markus Aarnio • Tue, Aug 28, 2012 • 2 Comments
19 High Growth Micro Cap Stocks Under $10
Kurtis Hemmerling • Sun, Jan 23, 2011 • 31 Comments
Three Recent Biotech Activist Wins by Carl Icahn
Michael Becker • Mon, Aug 31, 2009 • 4 Comments
26 Bullish Breakout Stocks on Big Volume
Option Maestro • Tue, Aug 4, 2009 • 2 Comments
Carl Icahn's Top Three Stock Ideas
The Manual of Ideas • Thu, Mar 5, 2009 • 2 Comments
Cancer Stocks Hammered Once Again
Alan Brochstein • Tue, Jun 26, 2007 • 7 Comments
Cancer Stocks Slide Again
Alan Brochstein • Mon, Jun 18, 2007 • 1 Comment
Cancer Stocks Plunge Following ASCO Meeting
Alan Brochstein • Mon, Jun 11, 2007 • 3 Comments
Cancer Stocks Soar With Annual ASCO Meeting
Alan Brochstein • Mon, Jun 4, 2007 • 1 Comment
Cancer Stocks on the Go: Winners and Losers
Alan Brochstein • Tue, May 29, 2007 • 3 Comments
Top 10 Insider Microcap Stock Picks
Microcap Speculator • Mon, Mar 19, 2007
Icahn Management: Notable 13F Changes
Lon Juricic • Sun, Feb 18, 2007 • 1 Comment
Biotech Day In Review: Osiris Stem Cells Treatment Has Unexpected Results
Centient Biotech Investor • Thu, Feb 15, 2007
Biotech Day In Review: Accuray Had Spectacular IPO
Centient Biotech Investor • Fri, Feb 9, 2007
Russell 3000's Best, Worst Performing Stocks, Year to Date
TickerSense • Sat, Feb 3, 2007
Russell 3000's Best, Worst Stocks Year to Date
TickerSense • Sun, Jan 28, 2007
Russell 3000's Best, Worst Stocks Year to Date
TickerSense • Mon, Jan 22, 2007
A Good Start for Biotech, Two Weeks in a Row
Centient Biotech Investor • Wed, Jan 17, 2007 • 1 Comment

Telik, Inc. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Telik Inc. Q1 2008 Earnings Call Transcript
Tue, May 27, 2008

Telik Announces First Quarter 2013 Financial Results

PR Newswire (May 10, 2013)
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance

PR Newswire (Mar 15, 2013)
Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome

PR Newswire (Jan 22, 2013)
Telik Announces Orphan Designation Of Telintra® For Treatment Of Myelodysplastic Syndrome

PR Newswire (Jan 11, 2013)
Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology

PR Newswire (Dec 12, 2012)
Telik Announces Third Quarter 2012 Financial Results

PR Newswire (Nov 9, 2012)
Health Care Sector Wrap

at Fox Business (Aug 15, 2012)
Health Care Sector Wrap

at Fox Business (Aug 15, 2012)
Health Care Sector Wrap

at Fox Business (Aug 15, 2012)
Telik Announces Second Quarter 2012 Financial Results

PR Newswire (Aug 10, 2012)
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome

PR Newswire (May 15, 2012)
Telik Announces First Quarter 2012 Financial Results

PR Newswire (May 9, 2012)
Telik Regains Compliance With Minimum Bid Price Requirement

PR Newswire (Apr 17, 2012)
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference

PR Newswire (Jan 4, 2012)
Telik Announces the Results of Genetic Signature Studies of Myelodysplastic Syndrome Patients Likely to Respond to Telintra® (Ezatiostat Hydrochloride, TLK199) at the Annual Meeting of the American Society of Hematology

PR Newswire (Dec 13, 2011)
Telik Announces Phase 1 Results of a Multicenter Study of Telintra® (Ezatiostat Hydrochloride, TLK199) in Combination with Revlimid® (Lenalidomide) in Patients with Myelodysplastic Syndrome

PR Newswire (Dec 13, 2011)

TELK vs. ETF Alternatives

Company Description

Currently, there's no company description for TELK.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, January 23, 10:24 AM Shares of Telik (TELK +11.8%) settle in to trade solidly higher after a volatile open on heavy volume after the company announced late yesterday that it had reached an agreement with the FDA on its Phase 3 Telintra design. The stock had initially soared over 22% in the pre-trade session. Comment! [Healthcare, On the Move]
Wednesday, January 23, 9:10 AM Premarket gainers: MAPP +59%. TELK +23%. CREE +14%. ISRG +9%. RFMD +6%. ACAD +6%. GOOG +5%.
Losers: COH -17%. MCP -14%. NMRX -14%. STSI -11%. BNNY -8%. GD -5%. 1 Comment [On the Move]
Tuesday, January 22, 5:39 PM Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment Telintra, with a preliminary agreement reached regarding the design of a Phase 3 trials. In order to focus its resources on the registration program, Telik has decided to stop further enrollment in its ongoing Phase 2 exploratory trials. Comment! [Healthcare]
Tuesday, January 15, 12:45 PM Midday top 10 gainers: EXPR +22%. EGAN +20%. ENOC +19%. FSGI +15%. GBR +15%. NVTL +13%. RSYS +12%. BGFV +11%. DOM +10%. ETAK +10%.
Midday top 10 Losers: COOL -32%. MFLX -22%. MEAD -20%. CWTR -20%. GMAN -16%. BODY -15%. TELK -15%. KGJI -13%. RBPAA -12%. GIVN -12%. Comment! [On the Move]
Tuesday, January 15, 9:10 AM Premarket gainers: EXPR +14%. QLGC +8%. SNTS +8%. RSH +6%.
Losers: COOL -32%. GIVN -14%. BODY -12%. LULU -6%. TELK -6%. SAP -5%. Comment! [On the Move]
Monday, January 14, 12:45 PM Midday top 10 gainers: AZK +33%. NEWL +25%. CBAN +20%. THTI +17%. ADEP +17%. BIOL +15%. HALO +14%. CXPO +11%. FNP +10%. CTC +10%.
Midday top 10 Losers: TELK -22%. NTE -12%. APT -11%. EDMC -11%. MXT -9%. HGG -9%. SPRO -9%. CRUS -8%. CEDC -8%. CBMX -7%. Comment! [On the Move]
Monday, January 14, 11:48 AM Telik (TELK -21%) reverses course and gives back a big chunk of its +55% gain posted on Friday, after the company said its myelodysplastic syndrome treatment Telintra had been given an Orphan Drug designation by the FDA, which will give it U.S. market exclusivity for seven years. The stock is no stranger to volatility however, and Fridays move is just a drop in the bucket compared to the bigger picture for a stock that just less than a year ago had been trading at $8. 1 Comment [Healthcare, On the Move]
Friday, January 11, 1:48 PM Shares of Telik (TELK +57.2%) are soaring on heavy volume following a brief halt after the FDA grants orphan drug status for Telintra, a treatment for myelodysplastic syndrome. Comment! [Healthcare, On the Move]
Thursday, January 3, 12:45 PM Midday top 10 gainers: SPWR +38%. VISN +30%. MDCI +20%. FORD +20%. BGMD +19%. TSL +19%. CRDC +19%. FOLD +19%. TELK +18%. JASO +16%.
Midday top 10 Losers: LPH -73%. ALLT -23%. MLNX -14%. FDO -12%. AMPL -12%. TRIT -11%. PKT -10%. SSI -9%. LODE -9%. HPJ -9%. 1 Comment [On the Move]
Thursday, December 27, 2012, 12:45 PM Midday top 10 gainers: BCDS +92%. FSGI +19%. ENPH +15%. RGLS +11%. MNGA +10%. CLNT +9%. OSBC +9%. DECK +8%. BLIN +8%. PZE +7%.
Midday top 10 Losers: SSE -16%. SPMD -14%. GNI -12%. CIG -12%. CHC -14%. SARA -9%. TOWR -9%. TELK -9%. DQ -8%. AMRS -8%. Comment! [On the Move]
Thursday, December 13, 2012, 12:45 PM Midday top 10 gainers: ONCY +51%. TELK +23%. PRGN +21%. GBR +17%. SDBT +16%. SAM +15%. BBY +15%. CLWR +14%. ZAGG +14%. TROV +13%.
Midday top 10 Losers: RIGL -35%. EVI -31%. HRG -26%. PTIE -19%. CBMX -18%. OSN -15%. MEIP -13%. DQ -12%. CSUN -12%. ALLT -11%. Comment! [On the Move]
Thursday, December 13, 2012, 9:10 AM Premarket gainers: TELK +28%. ONCY +22%. BBY +17%. CLWR +13%. CVS +5%. TSL +5%.
Losers: RIGL -33%. HRG -26%. Comment! [On the Move]
Wednesday, December 12, 2012, 12:45 PM Midday top 10 gainers: YMI +77%. DSTI +73%. TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%.
Midday top 10 Losers: RSOL -14%. CENT -13%. ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. CRL -8%. AXK -8%. LTBR -8%. Comment! [On the Move]
Tuesday, December 11, 2012, 12:45 PM Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%. 2 Comments [On the Move]
Monday, December 10, 2012, 12:45 PM Midday top 10 gainers: CBMX +37%. UNXL +37%. ACUR +32%. GERN +25%. IN +23%. CLDX +23%. GPRC +20%. TELK +19%. SUMR +17%. EJ +16%.
Midday top 10 Losers: ZGNX -47%. CSFS -25%. MEAD -13%. TCCO -12%. GTIM -11%. SEV -10%. GEO -10%. BLIN -10%. DCTH -9%. NQ -9%. Comment! [On the Move]
Friday, December 7, 2012, 12:50 PM Midday top 10 gainers: CBMX +184%. GTIM +48%. LTBR +18%. DLGC +17%. RECV +16%. UNXL +15%. PAMT +15%. TELK +14%. JKS +14%. XPLR +11%.
Midday top 10 Losers: TOPS -23%. AMRN -19%. KUTV -15%. VTSS -13%. MBLX -11%. CHLN -11%. CHTP -9%. RGC -8%. CUR -8%. AACC -8%. Comment! [On the Move]

TELK Telik, Inc.

TELK

Telik, Inc.